William B. Hillegass

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial

Robert J. Lederman, Farrell O. Mendelsohn, R. David Anderson et al. · The Lancet · 2002 · 513 citations

Regenerative Medicine, Thrombosis, Translational Medicine +13

Adoption of Radial Access and Comparison of Outcomes to Femoral Access in Percutaneous Coronary Intervention

Dmitriy N. Feldman, Rajesh V. Swaminathan, Lisa A. Kaltenbach et al. · Circulation · 2013 · 461 citations

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Larisa H. Cavallari, Craig R. Lee, Amber L. Beitelshees et al. · JACC: Cardiovascular Interventions · 2017 · 303 citations

Percutaneous Coronary Intervention, Thrombosis, Multisite Investigation +10

Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative

Tellen D. Bennett, Richard A. Moffitt, Janos Hajagos et al. · JAMA Network Open · 2021 · 239 citations · Full text

Relation Between Activated Clotting Time During Angioplasty and Abrupt Closure

Craig R. Narins, William B. Hillegass, Charlotte Nelson et al. · Circulation · 1996 · 189 citations